Bal Pharma Ltd @100.50

1. Bal Pharma Ltd is a 10 rupee face value pharmaceuticals company.

 Security ID: BAL PHARMA Group / Index: B Face value: 10.00 Security Code: 524824 ISIN: INE083D01012 Industry: Pharmaceuticals. 

Brief Details of Company: -

Bal Pharma API (Active Pharmaceutical Ingredients) business began in 1996 with a simple objective of facilitating the manufacture of niche molecules that have been able to take the benefits of vertical integration to international and domestic markets.

Bal Pharma’s API business has the competence and knowledge to undertake more than 30 different types of complex chemical reactions. 

Whether these are Advance Intermediates, Fine Chemicals or Active Pharmaceuticals Ingredients, the company can seamlessly scale up from MG to MT quantities. 

It offers various activities like: 

State-of-the-art Pilot and Commercial Scale multipurpose facilities 

Pharmaceutical Manufacturing Plants conforming to GMP guidelines 

R & D facilities to support early development of Generic APIs 

Patent non-infringing processes High-quality documents – Drug master file 

The API products are being exported to Japan, Australia, Spain, UK, Canada, Nigeria, Iceland, Slovenia, Romania, Argentina, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, Turkey, Egypt, Korea, Venezuela, Italy, Portugal, Morocco, Poland, Netherlands, Syria, Bangladesh and Indonesia etc. 

The range of APIs includes Anti-Histamine, Platelet Inhibitor, Anti-Diabetic, Anti Convulsant, Urinary Incontinence, Neuropathic Pain, Anti Allergy, Anti Inflammatory, Diuretic, Acne Treatment, etc. 

The plant has various accreditations. Certification:-

 ISO 9001 – 2008 

Approval from EDQM for Gliclazide and Ebastine 

TGA approval for Gliclazide 

Approval from KFDA for Gliclazide and Ebastine COFEPRIS, 

MEXICO approval for Benzydamine HCl, Ebastine and Tolterodine tartrate 

Plant approved by MOH Iran and MOH Canada 

Only Indian company to be granted a COS for Gliclazide One of the first Indian companies to successfully file and receive approval by MHLW Japan 

Source:-http://www.balpharma.com/(Company Website)

2. Year high of Bal Pharma Ltd is 123.30 year low was 82.05 and stock traded at 100.50, Year high/ low ratio is below 2 ,If you read my research terms or my book then you may know that generally, I like a stock which year high/low ratio is below 2  If you are a new reader of my blog and not familiar with my research terms then please see my research terms at this link:-

Trading Research Terms of Mahesh Kaushik 

3. Promoters of Bal Pharma Ltd hold 44.44 %. 

Promoters holding is good, and promoters are not pledged any stock. 

Promoters also increased their holding from 44.35% to 44.44% increasing promoters holding is a good sign.

See FII & DII holding here:-

FII & DII Holding of Bal Pharma

Also watch this video to learn how to find out FII & DII holding:-

4.Bal Pharma Ltd Stock has a regular dividend history, and As you know most of my recommendations are dividend paying, so we get dividends in our holding periods. Past Dividends:- 

Dividend Declared (  )

EX Date Amount () 15 Sep 2016 1.0000 15 Sep 2015 1.0000 12 Sep 2014 1.0000 12 Sep 2013 0.7500 17 Sep 2009 0.7500 09 Sep 2008 1.0000 07 Sep 2007 0.7500 03 Sep 2001 1.0000

5. The base price of Bal Pharma Ltd is 85.78 So Stock is traded near 17% above from base price, and it is the best price for trading buy.In my book, you already read that buying range for a stock is 20% below to 20% up from base price, but if stock recently crosses base price from downside to upside, then it is the best price for buy see this chart and last 3-year closing price for more deep knowledge. 

Link for last 3-year close price and chart

6. No any bonus issue right issue and bulk deals are recorded in last 2 years.

7. Bal Pharma Ltd net sale per share of Fy 16-17 is 163.71. 

8. Net sale per share 163.71 is near 1.6 times higher from CMP 100.50 this is the another reason for this recommendation. 

9. The book value of Bal Pharma Ltd is 39.64 Book value is low from CMP, and this is the reason why I choose this stock for 20% trading gain instead of the fundamental recommendation. 

8. Finally, I choose Bal Pharma as trading stock for 20%+ returns in one to three months. 

9. 200 DMA of Bal Pharma Ltd is 97.34 So at CMP 100.50 Stock recently cross his 200 DMA, so I choose this level for my recommendation. 

10. If you buy my book "Top 100 Diversified Indian Stocks For FY17-18" then it is recommended to read all part of this free series:-सीमा कौशिक ने मेरी पुस्तक से अपना शेयर बाजार का रिस्क फ्री डायवर्सिफाईड पोर्टफोलियो कैसे बनाया?

Because it gives you a clear practical approach that how to use above book, If you do not know Hindi then please use google translate to read above link but all part of above link is recommended for every follower.

11. Disclaimer: - This is not an advisory service to buy or sell. The contents of “this research report” are only for educational purposes. No liability is accepted for any content in “this research report”. The author is neither a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time.The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions. Please read full disclaimer at the bottom of my blog. 

12.Discloser:- I Mahesh Chander Kaushik author of this research report is an existing research analyst and passed NISM certification for research analysts. I am also registered with SEBI(RESEARCH ANALYSTS) REGULATIONS, 2014 ( SEBI Registration Number INH 100000908 ) hereby disclose about my financial interest in the subject company and the nature of such financial interest:- 1 Me and my associates or relatives have not held any share of Bal Pharma Ltd so my personal interest is not included in this stock. 2. Me and my associates or relatives have not any actual/beneficial ownership of one percent or more securities of the subject company ( Bal Pharma Ltd). 3. Me and my associates or relatives have not any other material conflict of interest at the time of publication of the research report. 4. Me and my associates or relatives have not received any type of compensation from the subject company(Bal Pharma Ltd) in the past twelve months. 5. I am not served as an officer, director or employee of the subject company ( Bal Pharma Ltd). 6. I have been not engaged in market making activity for the subject company (Bal Pharma Ltd).